Skip to main content
. 2016 Feb 21;7(13):15959–15976. doi: 10.18632/oncotarget.7557

Figure 5. Characterization of the PI3K/AKT, MAPK, and JAK/STAT3 signaling pathways in PTEN-deficient prostate cancer in response to treatment with AZD5363.

Figure 5

A. Tumors lysates from control and AZD5363 treated mice (n = 6 per group) were pooled and were examined by western blot for the expression targets for PI3K/AKT, MAPK, and JAK/STAT3 signaling. Gel densitometry was quantified with ImageJ. Lanes were run on the same gel but were noncontiguous. B. IHC quantification of phosphorylated S6 (S235/236), ERK (T202/Y204) and STAT3 (Y705) proteins of tissue sections corresponding to A. Values represent mean ± s.e. C., Representative images of H&E and IHC staining patterns of Ki67, cleaved caspase-3, and phosphorylated S6 (S235/236), ERK (T202/Y204), and STAT3 (Y705) in vehicle and proliferative active regions in AZD5363 treated mice.